---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-22-000135"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:43:22.524079+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Castle Q2 revenue $34.8M (+53%); raises 2022 guidance to $130-135M

## Summary
- Q2 total test reports 11,034 (+57% YoY); skin cancer GEP volume up 44% YoY.
- Net loss $(1.6)M improved from $(8.8)M; adjusted EBITDA $(10.9)M vs $(3.4)M.
- 2022 revenue guidance raised to $130-135M from $118-123M; cash $273M.
- DecisionDx-Melanoma test linked to 27% improvement in melanoma-specific survival in NCI collaboration.

## SEC filing metadata
- accession: 0001447362-22-000135
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736222000135/0001447362-22-000135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736222000135/cstl-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-22-000135
- JSON: https://secwatch.observer/filing/0001447362-22-000135.json
- Plain text: https://secwatch.observer/filing/0001447362-22-000135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.